Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eligibility, and we studied 13 therapies. Most studies were at serious or critical RoB; no studies were at low RoB. One study, at moderate RoB, showed reduced mortality rates in severe MERS patients with extracorporeal membrane oxygenation; no other studies showed a significant lifesaving benefit to any treatment. The existing literature on treatments for MERS is observational and at moderate to critical RoB. Clinical trials are needed to guide treatment decisions.

中文翻译：

---

中东呼吸综合征的药物治疗和支持治疗。

现有的动物和细胞系模型表明，特定的治疗方法可能有效治疗中东呼吸综合征（MERS）。我们对药理和支持疗法治疗的证据进行了系统的回顾。我们制定了方案，并搜索了5个数据库以描述描述MERS治疗和MERS患者死亡的研究。使用ROBINS-I工具评估偏倚风险（RoB）。我们检索了3,660个独特的引文；符合条件的有20项观察性研究，我们研究了13种疗法。大多数研究处于严重或严重的RoB状态；RoB较低时没有研究。一项研究以中等RoB进行，结果显示严重MERS并伴有体外膜氧合的患者死亡率降低。没有其他研究显示任何治疗都能显着挽救生命。关于MERS治疗的现有文献是观察性的并且处于中等至临界RoB。需要临床试验来指导治疗决策。